Silverarc Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Silverarc Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-54,822	Closed	-$1.67M	–	90
2023 Q4	$1.67M	Buy	54,822 +1,804	+3%	+$51.8K	0.5%	53
2023 Q3	$1.68M	Buy	53,018 +2,160	+4%	+$83.8K	0.51%	50
2023 Q2	$2.07M	Buy	50,858 +13,000	+34%	+$527K	0.64%	45
2023 Q1	$1.41M	Buy	37,858 +5,088	+16%	+$200K	0.58%	52
2022 Q4	$1.14M	Buy	32,770 +759	+2%	+$36.1K	0.33%	66
2022 Q3	$1.79M	Buy	+32,011	New	+$1.99M	0.61%	48
2021 Q4	–	Sell	-4,950	Closed	-$664K	–	85
2021 Q3	$664K	Buy	+4,950	New	+$749K	0.38%	61

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Silverarc Capital Management's NTLA Position: Q1 2024 in Review

Silverarc Capital Management sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 54,822 shares — an estimated $1.67M sold.

Silverarc Capital Management first reported a position in NTLA in Q3 2021 and held it in 7 quarters. The position peaked at $2.07M in Q2 2023. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

Silverarc Capital Management reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
Silverarc Capital Management sold 54,822 Intellia Therapeutics shares in Q1 2024, an estimated $1.67M.
Silverarc Capital Management first reported a position in Intellia Therapeutics in Q3 2021 and held it in 7 quarters.
Silverarc Capital Management's Intellia Therapeutics position peaked at $2.07M in Q2 2023.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Silverarc Capital Management's 13F filing for Q1 2024, filed 15 May 2024.